Christopher D. Corsico, MD, MPH, is the new global head of Development at GSK, reporting to Chief Scientific Officer and President of R&D Hal Barron, and responsible for development oversight of the pharmaceutical pipeline starting from phase IIa through approval, excluding oncology, and the pharmaceutical marketed portfolio though the end of the life cycle.
Prior to joining GSK, Chris worked at Boehringer Ingelheim for over 20 years, his last several years as the Global Head of Medicine and Chief Medical Officer. Chris worked in the US organization in various roles including Head of Regional Pharmacovigilance, Head of US Regulatory Affairs and Medical Director, North America prior to moving to corporate headquarters in Q3 2012.
Chris received his medical degree from the Cornell University College of Medicine in New York City, New York and his MPH from the School of Public Health at Yale University in New Haven, Connecticut. Chris trained in Internal Medicine at the Johns Hopkins University School of Medicine. He practiced Internal Medicine at the Johns Hopkins Medical Clinical and was an Assistant Professor of Internal Medicine at the Dartmouth Hitchcock Medical Center and Dartmouth Medical School prior to joining industry.